Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09KQM
|
||||
| Former ID |
DIB009597
|
||||
| Drug Name |
PYK2 inhibitors
|
||||
| Synonyms |
PYK2 inhibitors (osteoporosis); FAK 2 inhibitors (osteoporosis), Pfizer; Focal adhesion kinase 2 inhibitors (osteoporosis), Pfizer; PYK2 inhibitors (osteoporosis), Pfizer; Proline-rich tyrosine kinase 2 inhibitors (osteoporosis), Pfizer
|
||||
| Indication | Osteoporosis [ICD9: 733.0, V07.4; ICD10:M80-M81, Z79.890] | Investigative | [552045] | ||
| Company |
Pfizer Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
N(=[S@@](=O)(c1ccc(Nc2ncc(C(F)(F)F)c(n2)N[C@H]2[C@H](N(<br />C)C)CCC2)cc1)C)C
|
||||
| Target and Pathway | |||||
| Target(s) | Focal adhesion kinase-2 | Target Info | Inhibitor | [543570] | |
| NetPath Pathway | TCR Signaling Pathway | ||||
| Pathway Interaction Database | Endothelins | ||||
| LPA receptor mediated events | |||||
| Coregulation of Androgen receptor activity | |||||
| Osteopontin-mediated events | |||||
| IL2-mediated signaling events | |||||
| CXCR4-mediated signaling events | |||||
| Integrins in angiogenesis | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Alpha-synuclein signaling | |||||
| FGF signaling pathway | |||||
| Alpha4 beta1 integrin signaling events | |||||
| WikiPathways | TCR Signaling Pathway | ||||
| IL-2 Signaling Pathway | |||||
| Signaling of Hepatocyte Growth Factor Receptor | |||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Interleukin-2 signaling | |||||
| Nifedipine Activity | |||||
| BDNF signaling pathway | |||||
| Oncostatin M Signaling Pathway | |||||
| Prostate Cancer | |||||
| IL-7 Signaling Pathway | |||||
| Signal regulatory protein (SIRP) family interactions | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.